Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ADDXFNASDAQ:AKTXNASDAQ:FCSCOTCMKTS:NMUSNASDAQ:VVUS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADDXFAddex Therapeutics$0.99$0.99$0.99▼$0.99N/A0.25N/AN/AAKTXAkari Therapeutics$1.22+3.4%$1.84$1.08▼$5.50$9.66M0.9612,352 shs4,786 shsFCSCFibrocell Science$3.00$3.00$1.45▼$3.28$29.28M1.6778,673 shsN/ANMUSNemus Bioscience$0.65-9.5%$10.59$0.05▼$0.74$87.04M-0.04377,395 shs1.00 million shsVVUSVIVUS$0.37$0.44▼$4.75$7.33M-0.841.44 million shs2.03 million shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADDXFAddex Therapeutics0.00%0.00%0.00%0.00%0.00%AKTXAkari Therapeutics+3.39%+5.17%-32.60%-54.14%-65.34%FCSCFibrocell Science0.00%0.00%0.00%0.00%0.00%NMUSNemus Bioscience0.00%-94.93%-94.58%-71.74%+4,477.46%VVUSVIVUS0.00%0.00%0.00%0.00%0.00%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/AN/AN/AN/AN/ANMUSNemus BioscienceN/AN/AN/AN/AN/AN/AN/AN/AVVUSVIVUSN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADDXFAddex TherapeuticsN/AN/AN/AN/AAKTXAkari TherapeuticsN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/ANMUSNemus BioscienceN/AN/AN/AN/AVVUSVIVUSN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AAKTXAkari TherapeuticsN/AN/AN/AN/A($0.03) per shareN/AFCSCFibrocell Science$350K83.66N/AN/A$0.98 per share3.06NMUSNemus BioscienceN/AN/AN/AN/A($0.12) per shareN/AVVUSVIVUS$69.76M0.00N/AN/A($6.50) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADDXFAddex TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AAKTXAkari Therapeutics-$10.01MN/A0.00∞N/AN/AN/AN/A5/6/2024 (Estimated)FCSCFibrocell Science-$10.28M-$1.45N/AN/AN/AN/A23.10%10.56%N/ANMUSNemus Bioscience-$19.19MN/A0.00∞N/AN/AN/A-924.42%N/AVVUSVIVUS-$31.50M-$2.96N/AN/AN/A-39.28%N/A-12.18%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADDXFAddex TherapeuticsN/AN/AN/AN/AN/AAKTXAkari TherapeuticsN/AN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/AN/ANMUSNemus BioscienceN/AN/AN/AN/AN/AVVUSVIVUSN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADDXFAddex TherapeuticsN/AN/AN/AAKTXAkari TherapeuticsN/A0.950.95FCSCFibrocell Science0.475.095.09NMUSNemus BioscienceN/A0.120.12VVUSVIVUSN/A0.430.28OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADDXFAddex TherapeuticsN/AAKTXAkari Therapeutics5.06%FCSCFibrocell Science36.72%NMUSNemus BioscienceN/AVVUSVIVUS7.32%Insider OwnershipCompanyInsider OwnershipADDXFAddex TherapeuticsN/AAKTXAkari Therapeutics61.80%FCSCFibrocell Science1.10%NMUSNemus Bioscience2.70%VVUSVIVUS12.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADDXFAddex Therapeutics26N/AN/ANot OptionableAKTXAkari Therapeutics157.92 million3.03 millionNot OptionableFCSCFibrocell Science199.76 millionN/AOptionableNMUSNemus BioscienceN/A133.91 millionN/ANot OptionableVVUSVIVUS5717.87 millionN/AOptionableFCSC, NMUS, VVUS, ADDXF, and AKTX HeadlinesSourceHeadlineVIVUS Provides Update on Pipeline and Program Milestonesmarkets.businessinsider.com - January 8 at 10:04 AMShark research group to build new global headquarters in Jacksonville with help from state fundingactionnewsjax.com - June 26 at 9:16 AMMetaview announces Answers, the world's first conversational AI for the interview processit.tmcnet.com - May 25 at 11:10 AMPancrelipase (CAS 53608-75-6) Market 2023 | Industry Growth ... - StreetBuzznews.google.com - May 12 at 2:58 AMExploring Huge Demand of Peripherally Acting Anti-Obesity Drug ... - Digital Journalnews.google.com - May 12 at 2:58 AMExtensive Growth Opportunities to be Witnessed by Prescription Weight-Loss Pills Market 2023 Analysis of Risin - openPRnews.google.com - May 11 at 8:54 AMErectile Dysfunction Drugs Market to Register High Demand Rate by ... - Cottonwood Holladay Journalnews.google.com - May 11 at 8:54 AMMilestone Pharmaceuticals Reports First Quarter 2023 Financial ... - PR Newswirenews.google.com - May 11 at 8:54 AMAnti-obesity Therapeutics Market to Witness the Highest Growth ... - Cottonwood Holladay Journalnews.google.com - May 11 at 3:54 AMAnti Obesity Drugs Market Future Industry Scope for New ... - Digital Journalnews.google.com - May 11 at 3:54 AMThis Crazy Six-Wheel Hatchback by Briggs & Stratton Was One of ... - autoevolutionnews.google.com - May 10 at 12:51 PMProstatic Artery Embolization Market Current and Upcoming Projects ... - Digital Journalnews.google.com - May 9 at 6:48 AMThis 1899 Porsche Pioneered Rivian's Quad-Motor Drive, Ram ... - MotorBiscuitnews.google.com - May 7 at 8:20 PMPorsche Pioneered the Range-Extended EV 100+ Years Before ... - MotorBiscuitnews.google.com - May 6 at 3:22 PMIncreasing Opportunities In Peripherally Acting Anti-Obesity Drug Market Latest Trends, Technological Advancem - openPRnews.google.com - May 5 at 1:45 PMNonalcoholic Steatohepatitis Treatment Market Outlook Growths ... - Digital Journalnews.google.com - May 5 at 7:44 AMA Big Fat Problem: Will children in the UK be given weight-loss injections? - Firstpostnews.google.com - May 2 at 10:24 AMIntraoperative Ultrasound Market Latest Trends, Techniques and Applications|2023-2030 - openPRnews.google.com - April 28 at 9:38 AMBuild Your Own Case Study | Obesity: Treating the Whole Patient - Healionews.google.com - April 27 at 8:14 PMBladder Cancer Market Demand in Various industries and Significant for Various Regions|2023-2030 - openPRnews.google.com - April 27 at 3:10 PMPediatric Obesity Management Market is projected to grow with a 4 ... - Future Market Insightsnews.google.com - April 27 at 10:10 AMGlobal Erectile Dysfunction Drugs Market Analysis by Recent Trends, Development, Regional Growth Overview and - openPRnews.google.com - April 26 at 7:33 AMNon-Alcoholic Steatohepatitis (NASH) Market Analysis, Trends, Growth, Research And Forecast 2032 - openPRnews.google.com - April 25 at 2:02 AMWhat to Know About Obesity and Bone Health - Health Centralnews.google.com - April 24 at 4:02 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAddex TherapeuticsOTCMKTS:ADDXFAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Akari TherapeuticsNASDAQ:AKTXAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Fibrocell ScienceNASDAQ:FCSCFibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.Nemus BioscienceOTCMKTS:NMUSNemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.VIVUSNASDAQ:VVUSVIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.